DALLAS, June 16, 2026 /PRNewswire/ -- Cizzle Bio, Inc., a Texas-based biotechnology company advancing biomarker blood tests for early detection of...
BEIJING, June 16, 2026 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated...
Leading Pediatric Osteosarcoma Nonprofit to Present $400,000 to 5 Scientists During Annual Conference to Find Kinder Treatments for Patients BARNARD,...
Dr. Stephen Hoge, President of Moderna, to Assume an Expanded Role With Operational Oversight of the Company's Infectious Disease, Intismeran...
SkinVision Pro connects AI-powered skin health assessments directly to medical practices, giving doctors structured information before the consultation begins. AMSTERDAM,...
NASHVILLE, Tenn., June 15, 2026 /PRNewswire/ -- Immorta Bio President Thomas Ichim and TAM Global's Chief Scientific Officer Francesco M....
Researchers find a two-pronged approach helps ensure people with cancer understand their illness better and share their priorities for care.PLYMOUTH...
New agreement with one of the world's top public health systems designed to boost local deal flow, affirms St. Louis...
SHELTON, CT / ACCESS Newswire / June 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
Insulin Resistance Was Normalized Following 14 Days of Treatment, Supporting Restoration of Glucose Metabolism and Insulin Sensitivity and Further Validating...
Company at a Turning Point — Moving the Business to a Different Level, With Growing Revenue and a Roadmap Toward...
Accomplished global commercial operations leader brings deep experience launching and scaling biopharmaceutical products as Fate advances its pipeline toward commercializationSAN...
VANCOUVER, BC / ACCESS Newswire / June 15, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience...
The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction...
Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL...
Media ReleaseCOPENHAGEN, Denmark; June 13, 2026 Results from the Phase 2 EPCORE® DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early...
TALVEY® plus daratumumab with or without pomalidomide showed progression-free survival of up to 81.3% and overall survival of up to 89.2% at 24...
The Twist Fast Hyb App joins Twist's Standard Hyb v2 App on Callisto, giving labs a fully walk-away path to...
The article outlines how insulin resistance affects liver health and increases risk for chronic disease.CRANBERRY TOWNSHIP, Pa., June 12, 2026...
Hartwig to adopt Ultima Genomics' UG200 sequencing system to accelerate implementation of whole-genome-based clinical genomics workflows on Solaris 2.0 technologyHartwig...